PMID- 34190188
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20221207
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 26
DP  - 2021 Jul 2
TI  - Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus: A 
      cross-sectional study.
PG  - e26529
LID - 10.1097/MD.0000000000026529 [doi]
LID - e26529
AB  - We aimed to evaluate sarcopenia and sarcopenic obesity (SO) in patients with type 
      2 diabetes mellitus (T2DM), possible relationships with serum irisin and 
      myostatin levels, and the effect of glycemic control on SO.Ninety T2DM patients 
      were included in this a cross-sectional study. Sarcopenia was determined by 
      evaluating muscle mass (bioelectrical impedance analysis), muscle strength (HGS), 
      and gait speed (GS). Patients with muscle mass loss with functionally reduced 
      muscle strength and/or performance were considered sarcopenic. In addition, 
      participants were divided into 3 groups according to the FM (fat mass)/FFM 
      (fat-free mass) ratio [group 1:5th-50th percentiles; group 2:50th-95th 
      percentiles and group 3: >/=95 percentiles (sarcopenic obese)]. Irisin, myostatin 
      levels and metabolic parameters were measured in all patients.The prevalence of 
      sarcopenia and SO was 25.6% and 35.6%, respectively. Irisin levels were lower in 
      sarcopenic patients, while glycosylated hemoglobin (A1c), body mass index (BMI), 
      FM, and FM index were higher (P < .05). From group 1 to group 3, BMI, FM, FM 
      index, GS, myostatin, and A1c increased, and muscle mass percentage, HGS, and 
      irisin decreased (P < .05). A positive correlation was found between FM/FFM and 
      myostatin and a negative correlation between FM/FFM and irisin (r = 0.303, 
      P = .004 vs. r = -0.491, P < .001). Irisin remained an important predictor of SO, 
      even after adjusting for confounding variables (OR:1.105; 95% CI:0.965-1.338, 
      P = .002). The optimal cut-off value for irisin to predict SO was 9.49 ng/mL 
      (specificity = 78.1%, sensitivity = 75.8%). In addition, A1c was an independent 
      risk factor for SO development (OR:1.358, P = .055).This study showed that low 
      irisin levels (<9.49ng/mL) and poor glycemic control in T2DM patients were an 
      independent risk factor, especially for SO.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Oguz, Ayten
AU  - Oguz A
AUID- ORCID: 0000-0002-9518-8610
AD  - Faculty of Medicine, Istinye University, Istanbul.
FAU - Sahin, Murat
AU  - Sahin M
AD  - Department of Endocrinology and Metabolism.
FAU - Tuzun, Dilek
AU  - Tuzun D
AD  - Department of Endocrinology and Metabolism.
FAU - Kurutas, Ergul B
AU  - Kurutas EB
AD  - Department of Biochemistry.
FAU - Ulgen, Cansu
AU  - Ulgen C
AD  - Department of Internal Medicine, Faculty of Medicine, Kahramanmaras Sutcu Imam 
      University, Kahramanmaras, Turkey.
FAU - Bozkus, Ozlem
AU  - Bozkus O
AD  - Department of Biochemistry.
FAU - Gul, Kamile
AU  - Gul K
AD  - Faculty of Medicine, Istinye University, Istanbul.
LA  - eng
GR  - 2019/2-34M/Bilimsel Arastirma Projeleri, Kahramanmaras Sutcu Imam University/
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (FNDC5 protein, human)
RN  - 0 (Fibronectins)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (MSTN protein, human)
RN  - 0 (Myostatin)
SB  - IM
MH  - Body Mass Index
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/blood/complications/diagnosis
MH  - Female
MH  - Fibronectins/*blood
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle Strength
MH  - Myostatin/*blood
MH  - *Obesity/blood/complications/diagnosis/physiopathology
MH  - Physical Functional Performance
MH  - Predictive Value of Tests
MH  - Prevalence
MH  - Risk Factors
MH  - *Sarcopenia/blood/diagnosis/physiopathology
MH  - Walking Speed
PMC - PMC8257893
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2021/07/01 06:00
MHDA- 2021/07/08 06:00
PMCR- 2021/07/02
CRDT- 2021/06/30 09:09
PHST- 2021/03/24 00:00 [received]
PHST- 2021/06/15 00:00 [accepted]
PHST- 2021/06/30 09:09 [entrez]
PHST- 2021/07/01 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
PHST- 2021/07/02 00:00 [pmc-release]
AID - 00005792-202107020-00047 [pii]
AID - MD-D-21-02350 [pii]
AID - 10.1097/MD.0000000000026529 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Jul 2;100(26):e26529. doi: 
      10.1097/MD.0000000000026529.